The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization

Abola, 2012, Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes, Atherosclerosis, 221, 527, 10.1016/j.atherosclerosis.2012.01.002 Mahoney, 2010, Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States, Circ Cardiovasc Qual Outcomes, 3, 642, 10.1161/CIRCOUTCOMES.109.930735 Peacock, 2011, The incidence and health economic burden of ischemic amputation in Minnesota, 2005–2008, Prev Chronic Dis, 8, A141 Hirsch, 2006, J Vasc Interv Radiol, 17, 1383, 10.1097/01.RVI.0000240426.53079.46 Norgren, 2007, Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), J Vasc Surg, 45, S5, 10.1016/j.jvs.2006.12.037 Dick, 2008, Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience, Radiology, 248, 297, 10.1148/radiol.2481071159 Rocha-Singh, 2007, Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease, Catheter Cardiovasc Interv, 69, 910, 10.1002/ccd.21104 Krankenberg, 2007, Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST), Circulation, 116, 285, 10.1161/CIRCULATIONAHA.107.689141 Bosiers, 2011, Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions, J Vasc Surg, 54, 1042, 10.1016/j.jvs.2011.03.272 Schillinger, 2006, Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery, N Engl J Med, 354, 1879, 10.1056/NEJMoa051303 Laird, 2010, Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial, Circ Cardiovasc Interv, 3, 267, 10.1161/CIRCINTERVENTIONS.109.903468 Steinfeld, 2012, Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and pro-inflammatory biomarker expression, J Cardiovasc Pharmacol, 60, 179, 10.1097/FJC.0b013e31825aa742 Scheller, 2003, Contrast media as carriers for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model, Eur Heart J, 24, 1462, 10.1016/S0195-668X(03)00317-8 Scheller, 2004, Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis, Circulation, 110, 810, 10.1161/01.CIR.0000138929.71660.E0 Scheller, 2006, Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter, N Engl J Med, 355, 2113, 10.1056/NEJMoa061254 Unverdorben, 2009, Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis, Circulation, 119, 2986, 10.1161/CIRCULATIONAHA.108.839282 Tepe, 2008, Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg, N Engl J Med, 358, 689, 10.1056/NEJMoa0706356 Werk, 2008, Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial, Circulation, 118, 1358, 10.1161/CIRCULATIONAHA.107.735985 Krucoff, 2008, A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study, J Am Coll Cardiol, 51, 1543, 10.1016/j.jacc.2008.01.020 Lansky, 2004, Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial, Circulation, 109, 1948, 10.1161/01.CIR.0000127129.94129.6F Stone, 2004, A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease, N Engl J Med, 350, 221, 10.1056/NEJMoa032441 Aoki, 2005, One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer: insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES), EuroIntervention, 1, 165 Cremers, 2009, Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model, Clin Res Card, 98, 325, 10.1007/s00392-009-0008-2 Pósa, 2010, Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries, Catheter Cardiovasc Interv, 76, 395, 10.1002/ccd.22468 Unverdorben, 2010, Treatment of small coronary arteries with a paclitaxel-coated balloon catheter, Clin Res Cardiol, 99, 165, 10.1007/s00392-009-0101-6 Cortese, 2010, Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial: the PICCOLETO study, Heart, 96, 1291, 10.1136/hrt.2010.195057 Gianni, 1995, Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans, J Clin Oncol, 13, 180, 10.1200/JCO.1995.13.1.180